Skip to main content

Table 1 Summary of PD-L1 assays and response rates in immune checkpoint inhibitor trials in metastatic urothelial carcinoma

From: Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond

Ref Population Drug Target Antibody for PD-L1 IHC Assay Definition of PD-L1 positivity ORR (PD-L1+) ORR (PD-L1-) ORR All Patients
[6] Post Platinum Atezolizumab PD-L1 Rabbit SP142 (Ventana) IHC 2/3 ICa 43% (13/30) 11% (4/35) 26% (17/65)
[7] Post Platinum Atezolizumab PD-L1 Rabbit SP142 (Ventana) IHC 2/3 ICa 23% (26/113) 10% (36/349) 13% (63/462)
[3] Post Platinum Atezolizumab PD-L1 Rabbit SP142 (Ventana) IHC 2/3 ICa 26% (26/100) 9% (19/210) 15% (45/310)
[1] Post Platinum Pembrolizumab PD-1 Mouse 22C3 (Dako) CPS ≥ 10%b 22% (16/74) 22% (41/186) 21% (57/270)
[5] Post Platinum Nivolumab PD-1 Rabbit 28–8 (Dako) PD-L1 ≥ 5% (TC) 28% (23/81) 16% (29/184) 20% (52/265)
[7] Post Platinum Durvalumab PD-L1 Rabbit SP263 (Ventana) ≥25% TC or ≥25% IC 28% (27/98) 5% (4/79) 18% (34/191)
[10] Post Platinum Avelumab PD-L1 Rabbit 73–10 (Dako) ≥5% TC 54% (7/13) 4% (1/24) 21% (8/37)
[50] Platinum Ineligible Pembrolizumab PD-1 Mouse 22C3 (Dako) CPS ≥ 10%b 51% (41/80) 23% (42/185) 31% (83/265)
[12] Platinum Ineligible Atezolizumab PD-L1 Rabbit SP142 (Ventana) IHC 2/3 ICa 28% (9/32) 20% (18/87) 22% (27/119)
  1. TC tumor cells, Ref reference, IC percentage of PD-L1 positive immune cells in the tumor microenvironment, ORR overall response rate
  2. aIHC 2 is ≥5%, IHC 3 is ≥10%
  3. bCombined Positive Score = percentage of PD-L1 expressing tumor and infiltrating immune cells relative to the total number of tumor cells